Avicanna’s (TSX:AVCN) PwdRx platform Shows Improved Cannabinoid Bioavailability in Studies

TORONTO, November 19, 2025 — Leads & Copy — Avicanna Inc. announced positive preclinical results and the filing of a provisional patent application for its novel Powder Drug Delivery System (PwdRx) platform.

The biopharmaceutical company developed the drug delivery platform to address formulation challenges associated with lipophilic cannabinoids such as CBD, CBG, THC, and CBN. These compounds often exhibit poor water solubility, low bioavailability, variable bioavailability, and delayed onset of action.

Preclinical pharmacokinetic studies showed that PwdRx formulations demonstrated enhanced bioavailability and faster uptake compared to conventional medium-chain triglyceride (MCT) oil-based formulations.

Recent in-vitro studies of Avicanna’s PwdRx technology showed statistically significant results, including 74% higher bioavailability (AUC), 63% faster peak plasma levels (TMAX), and a 134% higher peak plasma concentration (CMAX) when compared to MCT oil formulations.

In addition to enhanced bioavailability and faster uptake, the technology is designed to deliver long-term stability and manufacturing versatility, supporting scalable pharmaceutical production in solid-oral and powder-based formats such as tablets, capsules, sachets, and pouches.

The pharmaceutical dosage form offers tunable drug release capabilities to enable differentiated product profiles and tailor to specific patient needs.

According to Dr. Karolina Urban, EVP, Medical and Scientific Affairs of Avicanna, the PwdRx platform has the potential to enable health care providers greater flexibility to tailor potential treatment options for patients managing conditions associated with pain and inflammation by improving dispersion, solubility, and consistency of uptake.

The provisional patent filing covers the composition, methods of use, and potential utility of the PwdRx platform in pain and inflammation, including conditions such as rheumatoid arthritis, osteoarthritis, neuropathic pain, fibromyalgia, migraine, and multiple sclerosis.

Aras Azadian, Chief Executive Officer of Avicanna, said that the advancement of the PwdRx platform represents another significant step forward in the science and technology of cannabinoid delivery and further strengthens the company’s global intellectual property portfolio.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

For more information about Avicanna, contact Ivana Maric by email at info@avicanna.com.

Source: Avicanna Inc.

×

Welcome!

CannabisReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy

By Subscribing you will receive Daily Cannabis Story Leads via email 10:30 am ET Mon-Fri.